Sally E. Moore

Bristol, ENG, United Kingdom

Last Updated: 09/26/2026

Save publications for later

Sign Up

Not sure about your diagnosis?

Check Your Symptoms

Found 36 publications

Belantamab mafodotin-associated keratopathy: Clinical outcomes and management from two UK tertiary centres.

Belantamab mafodotin-associated keratopathy: Clinical outcomes and management from two UK tertiary centres.

Journal: British journal of haematology

Published: February 20, 2026

High-throughput monoclonal gammopathy community monitoring programme.

High-throughput monoclonal gammopathy community monitoring programme.

Journal: British journal of haematology

Published: July 23, 2025

NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma.

NGS-based targeted sequencing guides risk-adapted and molecularly targeted therapy decisions in multiple myeloma.

Journal: British journal of haematology

Published: April 17, 2025

Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group.

Assessment and treatment of frail patients living with multiple myeloma. A guideline on behalf of the UK Myeloma Research Alliance Frailty Group.

Journal: British journal of haematology

Published: April 08, 2025

Real-world characteristics and outcomes of patients with multiple myeloma receiving second-line treatment in England.

Real-world characteristics and outcomes of patients with multiple myeloma receiving second-line treatment in England.

Journal: EJHaem

Published: October 02, 2024

A 16-week progressive exercise training intervention in treatment-naïve chronic lymphocytic leukaemia: a randomised-controlled pilot study.

A 16-week progressive exercise training intervention in treatment-naïve chronic lymphocytic leukaemia: a randomised-controlled pilot study.

Journal: Frontiers in oncology

Published: July 29, 2024

Exploring the role of circulating proteins in multiple myeloma risk: a Mendelian randomization study.

Exploring the role of circulating proteins in multiple myeloma risk: a Mendelian randomization study.

Journal: Scientific reports

Published: July 25, 2024

Plasma cell disorders supress mucosal anti-bacterial immunity: another dimension of immunoparesis in plasma cell neoplasms.

Plasma cell disorders supress mucosal anti-bacterial immunity: another dimension of immunoparesis in plasma cell neoplasms.

Journal: Leukemia

Published: May 13, 2024

Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro.

Characterising how a single bout of exercise in people with myeloma affects clonal plasma cell and immune effector cell frequency in blood, and daratumumab efficacy in vitro.

Journal: Brain, behavior, & immunity - health

Published: April 25, 2024

Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro.

Downhill running does not alter blood C1q availability or complement-dependent cytotoxicity of therapeutic monoclonal antibodies against haematological cancer cell lines in vitro.

Journal: Scientific reports

Published: March 28, 2024

A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo.

A single bout of vigorous intensity exercise enhances the efficacy of rituximab against human chronic lymphocytic leukaemia B-cells ex vivo.

Journal: Brain, behavior, and immunity

Published: October 18, 2023

Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.

Longitudinal dynamics and clinically available predictors of poor response to COVID-19 vaccination in multiple myeloma.

Journal: Haematologica

Published: September 17, 2023

Showing 1-12 of 36

Last Updated: 09/26/2026